IMRX vs ARQT

Analysts rate Immuneering Corporation (IMRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcutis Biotherapeutics, Inc.

(ARQT) delivered a total return of -16. 2%, compared to -76. 2% for Immuneering Corporation (IMRX). Over 10 years, the gap is even starker: ARQT returned +11. 8% versus IMRX's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immuneering Corporation (IMRX) is the lower-risk stock at 1.

33β versus Arcutis Biotherapeutics, Inc. 's 1. 45β — meaning ARQT is approximately 9% more volatile than IMRX relative to the S&P 500. On balance sheet safety, Immuneering Corporation (IMRX) carries a lower debt/equity ratio of 2% versus 3% for Arcutis Biotherapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc.

grew EPS 88. 8% year-over-year, compared to 37. 7% for Immuneering Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immuneering Corporation (IMRX) is the more profitable company, earning 0.

0% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMRX leads at 0. 0% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMRX: 186.

4% to $12. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immuneering Corporation (IMRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Both have compounded well over 10 years (IMRX: -76. 2%, ARQT: +11. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMRX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.